

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: October 6, 2016	
Re.: Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated October 6, 2016, titled "Zydus signs in-licensing deal with Neovii of Switzerland to launch Grafalon^R, an immunosuppresant extensively used in solid organ transplants and Stem Cell Transplant in India". The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **Cadila Healthcare Limited**


Upen H. Shah
Company Secretary



Encl.: As above

Zydus signs in-licensing deal with Neovii of Switzerland

Launches Grafalon, one of the world's leading transplant-immuno therapies

Ahmedabad October 6, 2016

The Ahmedabad headquartered, Zydus group has entered into an in-licensing agreement with Neovii, a Switzerland based global biopharmaceutical company to launch Grafalon®, an immunosuppressant extensively used in solid organ transplants and Stem Cell Transplant in India. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine. With the inclusion of Grafalon®, Zydus Trans-immune becomes a leading player in transplant-immuno therapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant. The market for transplant-immuno therapies is estimated at Rs. 483 crore. (Source IPSOS)

Organ transplantation is the most preferred option for patients with end-stage organ failure since both survival and quality of life are superior as compared to patients who live without transplantation. However, one of the major challenges in organ transplantation is graft rejection. In most cases, transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Likewise, Stem Cell Transplantation remains key treatment option for those suffering from haematological conditions including malignancies. Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon®.

Grafalon® (formerly commercialized as ATG Fresenius) is used as a part of immunosuppressive regimens (induction protocol) for the prevention and treatment of rejection in solid organ transplantation, prevention of graft versus host disease in stem cell transplantation.

As an rATG anti-human T-lymphocyte globulin, Grafalon® enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of transplant recipients around the world. More than 200,000 patients till date, in over 50 countries, have been treated with Grafalon®.

Currently an estimated 10000 solid organ transplant & stem cell transplants are taking place annually across 200 plus transplant centres in India. Grafalon® offers a specific advantage of efficacy and better safety profile through targeted immunosuppression.

###